[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 63, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 64, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 677467, "exercisedValue": 0, "unexercisedValue": 52440}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.99, "open": 7.01, "dayLow": 6.905, "dayHigh": 7.71, "regularMarketPreviousClose": 6.99, "regularMarketOpen": 7.01, "regularMarketDayLow": 6.905, "regularMarketDayHigh": 7.71, "payoutRatio": 0.0, "beta": 2.66, "forwardPE": -0.97223705, "volume": 49749, "regularMarketVolume": 49749, "averageVolume": 73755, "averageVolume10days": 53620, "averageDailyVolume10Day": 53620, "bid": 6.71, "ask": 9.02, "bidSize": 1, "askSize": 2, "marketCap": 42521252, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 24.325, "allTimeHigh": 937.75, "allTimeLow": 3.76, "priceToSalesTrailing12Months": 16.070013, "fiftyDayAverage": 9.1862, "twoHundredDayAverage": 8.484475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -50509748, "profitMargins": 0.0, "floatShares": 3138388, "sharesOutstanding": 5353582, "sharesShort": 293582, "sharesShortPriorMonth": 240691, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0477, "heldPercentInsiders": 0.10366, "heldPercentInstitutions": 0.5516, "shortRatio": 3.77, "shortPercentOfFloat": 0.055999998, "impliedSharesOutstanding": 6153582, "bookValue": 11.674, "priceToBook": 0.59191364, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -86462000, "trailingEps": -13.54, "forwardEps": -7.10732, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -19.089, "enterpriseToEbitda": 0.589, "52WeekChange": -0.69328654, "SandP52WeekChange": 0.11471915, "quoteType": "EQUITY", "currentPrice": 6.91, "targetHighPrice": 175.0, "targetLowPrice": 20.0, "targetMeanPrice": 68.2, "targetMedianPrice": 50.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 99096000, "totalCashPerShare": 16.104, "ebitda": -85820000, "totalDebt": 6065000, "quickRatio": 4.507, "currentRatio": 4.704, "totalRevenue": 2646000, "debtToEquity": 8.443, "revenuePerShare": 0.299, "returnOnAssets": -0.54704, "returnOnEquity": -1.4182401, "grossProfits": -65800000, "freeCashflow": -45352752, "operatingCashflow": -79161000, "revenueGrowth": -0.416, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -38.27395, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "exchange": "NCM", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 6.91, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "postMarketChangePercent": 1.3024625, "postMarketPrice": 7.0, "postMarketChange": 0.09000015, "regularMarketChange": -0.0799999, "regularMarketDayRange": "6.905 - 7.71", "marketState": "CLOSED", "regularMarketChangePercent": -1.14449, "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 73755, "fiftyTwoWeekLowChange": 3.1499999, "fiftyTwoWeekLowChangePercent": 0.83776593, "fiftyTwoWeekRange": "3.76 - 24.325", "fiftyTwoWeekHighChange": -17.415, "fiftyTwoWeekHighChangePercent": -0.7159301, "fiftyTwoWeekChangePercent": -69.32865, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -13.54, "epsForward": -7.10732, "epsCurrentYear": -7.58788, "priceEpsCurrentYear": -0.9106628, "fiftyDayAverageChange": -2.2762003, "fiftyDayAverageChangePercent": -0.24778475, "twoHundredDayAverageChange": -1.5744753, "twoHundredDayAverageChangePercent": -0.18557133, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "corporateActions": [], "postMarketTime": 1771021780, "regularMarketTime": 1771016402, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-14"}]